FA
TNDM icon

Fagan Associates’s Tandem Diabetes Care TNDM Stock Holding History

Fagan Associates’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,840
Closed -$776K – 119
2020
Q3 		$776K Sell
6,840
-10,365
-60% -$1.09M 0.22% 67
2020
Q2 		$1.7M Buy
+17,205
New +$1.37M 0.54% 48

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fagan Associates's TNDM Position: Q4 2020 in Review

Fagan Associates sold out of Tandem Diabetes Care (TNDM) in Q4 2020, closing a stake of 6,840 shares — an estimated $776K sold.

Fagan Associates first reported a position in TNDM in Q2 2020 and held it in 2 quarters. The position peaked at $1.7M in Q2 2020. 309 funds tracked by Wall St. Rank hold TNDM as of Q4 2020.

  • Fagan Associates reported no remaining Tandem Diabetes Care position as of Q4 2020 after selling out during the quarter.
  • Fagan Associates sold 6,840 Tandem Diabetes Care shares in Q4 2020, an estimated $776K.
  • Fagan Associates first reported a position in Tandem Diabetes Care in Q2 2020 and held it in 2 quarters.
  • Fagan Associates's Tandem Diabetes Care position peaked at $1.7M in Q2 2020.
  • 309 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2020.

Based on Fagan Associates's 13F filing for Q4 2020, filed 8 Feb 2021.